Navigation Links
Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
Date:12/11/2008

ly enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. QMed, Inc. Reports July Medicare SNP Enrollments
2. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
3. SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder
4. Human Genome Sciences Completes Enrollment Ahead of Schedule in Second Phase 3 Albuferon(R) Trial
5. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
8. Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease
9. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
10. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
11. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... Proove Biosciences, Inc. is a finalist ... Annual High Tech Awards. , Now in its 22nd year, this premier awards event ... here, across the nation and around the world. The OC Tech Alliance will announce ...
(Date:8/28/2015)... ... August 28, 2015 , ... Proove Biosciences ... the International Spine Intervention Society’ s 23rd Annual Scientific Meeting (ASM). ... 2015. With a focus on evidence-based research and clinical application, the event gathered ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Since the initial launch of FireflySci Inc. ... quirky humor and excellent customer service. Images such as the Fonz in a lab ... add some flavor to the humdrum spectroscopy field. , FireflySci is proud to ...
(Date:8/27/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC ... Pharmaceutical Holding Company Limited (Biohaven), announced today that ... of BHV-0223, a glutamate modulating agent. Biohaven filed ... recently obtained clearance from the U.S. Food and ... Portage holds 54% equity interest in Biohaven, a ...
Breaking Biology Technology:Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... Technology (NIST) and the Naval Research Laboratory have developed ... semiconductor crystal by prodding it with a scanning tunneling ... will enable researchers to selectively implant atoms in a ... electrical and magnetic properties on the atomic scale. ...
... , HOUSTON, Dec. 3 JourneyLite ... facility to offer patients a second surgical option, vertical sleeve ... currently performs. The first sleeve gastrectomy procedure at the facility was ... October 20, 2009. The patient is reported as doing well. , ...
... , TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: ... results for the second quarter of fiscal year 2010 on December ... call and webcast to discuss the results at 11:30 a.m. EST ... results for the second quarter ended October 31, 2009 and will ...
Cached Biology Technology:NIST researchers put a new spin on atomic musical chairs 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2
(Date:8/10/2015)... 10, 2015 The latest 364 page ... analysis of the global border security market . ... $16.4bn in 2015. Now: Border security is hard ... of the business critical issue you need to know about ... ,s objective analysis of how this will impact your company ...
(Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
(Date:8/5/2015)... , August 5, 2015 According ... Access Management Market by Software, Services, Vertical (BFSI, Airport, IT ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... Market globally into various segments. The global PIAM Market ... to $546.2 Million by 2019, at a CAGR of ...
Breaking Biology News(10 mins):Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... unknown movements of a set of specialized cells, Whitehead ... immune system mounts a successful defense against hostile, ever-changing ... the activity inside structures known as germinal centers (GCs), ... of a foreign virus or bacteria. Within the GCs, ...
... In a study published in Cell Research , ... the genome sequencing and analysis of the endangered Chinese ... published crocodilian genome, providing a good explanation of how ... determination (TSD). The Chinese alligator is a ...
... The Netherlands , August 9, 2013 ... employment market, recruiters and HR specialists need to increase ... Microsoft Dynamics and WCC ELISE for organisations keen to ... Today,s recruiters must grapple with ever-increasing amounts ...
Cached Biology News:Helper cells aptly named in battle with invading pathogens 2Whole-genome sequencing uncovers the mysteries of the endangered Chinese alligator 2Most Efficient Matching in Recruitment With CRMATCH and ELISE 2
Contact us for more information...
Rabbit polyclonal to Quinaldic Acid ( Abpromise for all tested applications). Antigen: Synthetic peptide Quinaldic Acid conjugated to a protein carrier....
... is one of the several main MAP ... as a sensitive reporter for studying gene ... increase in sensitivity in comparison to the ... catalyzes the oxidative carboxylation of luciferin, a ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
Biology Products: